Cytotoxicity assessment of nanoliposomal Paclitaxel and nanoliposomal Hydroxyurea in MCF-7 cells

Abstract

Nanotechnology has revolutionized diagnosis and treatment of cancers. Breast cancer is one<br />of the most prevalent cancers among women. Paclitaxel and hydroxyurea are important drugs<br />in treatment of breast cancer but their use is limited due to a series of significant side effects.<br />On the other hand, nanoliposomes are widely used as nanocarriers for targeted drug delivery.<br />In this study, cytotoxic effects of nanoliposomal hydroxyurea and nanoliposomal Paclitaxel<br />were investigated. Liposomes were prepared using reversed phase evaporation.Cytotoxicity of<br />liposomal formulations of the drugs was determined using Methylthiazolyldiphenyl-tetrazolium<br />bromide (MTT) method. Results showed an IC50 level of 86.25 μl/ml for nanoliposomal<br />Hydroxyureaand and 43.78 μl/ml for nanoliposomal Paclitaxel. In general, it can be concluded<br />that that cytotoxicity of nanoliposomal drugs are higher than that of standard formulations.